
First quarter 2026
Q1 2026 results were reviewed by management during a live audio webcast with the financial community on April 23, 2026. The presentation was followed by a Q&A session.
Press Releases
June 23, 2026
Press Release: Sanofi’s Wayrilz approved in Japan to treat immune thrombocytopenia
June 23, 2026
Press Release: Sanofi’s Cenrifki (tolebrutinib) approved in the EU as the first disability-targeting medicine for secondary progressive multiple sclerosis without relapses
June 22, 2026
Press Release: Sanofi appoints Paulo Fontoura as Global Head of R&D
Upcoming Events
18Jun
2026
JPM European Healthcare Forum l London
Conferences
30Jul
2026
Second quarter 2026 results
Second quarter 2026 results will be reviewed by management during a live audio webcast with the financial community on July 30, 2026. The presentation will be followed by a Q&A session.
13:00 - 14:15 CET (7:00am - 8:15am EST)
Quarterly results
9Sep
2026
Kepler Cheuvreux Autumn Conference l Paris
Speaker : Thomas Grenier, Head of North America, Vaccines
Conferences


31st Consecutive Year of Dividend Increase

Environment, Social, Governance
As a global pharmaceutical company, we stretch everyday to deliver safe and sustainable innovation and play our part in addressing some of the world’s most pressing challenges.
Contact Our Investor Relations Team
For general inquiries
Please contact the switchboard, +33 (0)1 53 77 40 00
